Zyngenia is a privately-held biopharmaceutical company that is developing drugs to address diseases where there is great unmet medical need, such as cancer, inflammation and autoimmune disorders. The company was founded in 2008 and is headquartered in Montgomery County, Maryland, USA.

Zyngenia is focused on the development of a new class of multi-specific bio-therapeutics that more effectively treat human diseases by simultaneously targeting multiple biological pathways. The company uses its proprietary technology to develop monoclonal antibody-based therapeutics (each known as a Zybody) that are able to concomitantly engage multiple disease targets. Through these multi-specific interactions, these novel drugs are better able to address multifactorial and complex diseases such as cancer, inflammation and autoimmune disorders.

The company is creating its own pipeline of multi-specific proteins to treat cancer and forming partnerships to leverage the power of its technology throughout the biopharmaceutical industry.